drugset / Trial / NCT04442048
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
Phase 3
Completed
195 enrolled
Canadian Cancer Trials Group
ATGen Canada Inc · collabBioCan Rx · collabCanadian Cancer Society (CCS) · collabCanadian Centre for Applied Research in Cancer Control (ARCC) · collabImmodulon Therapeutics Ltd · collabOntario Institute for Cancer Research · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2024-05-07
- Completion
- 2025-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM-101 | Other / unclassified | 0.5 mg | — |